Frontotemporal Dementia Clinical Trial
Official title:
Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial
Frontotemporal dementia (FTD) is a devastating neurodegenerative disorder. It is the second most frequent cause of presenile neurodegenerative dementia in those less than 65 years of age. Currently, there is no effective pharmacological treatment to slow down the progression of FTD. Recently, it has been proposed that neuroinflammation could be involved in specific forms of FTD and that novel drugs targeting neuroinflammation could potentially be useful in FTD treatment. An available form of ultra-micronized PEA combined with luteoline (PEA-LUT) has gained attention for its proven anti-inflammatory and neuroprotective properties reported in neurodegenerative conditions related to FTD, such as Amyotrophic Lateral Sclerosis. The administration of PEA-LUT treatment may have a clinical impact in behavioural variant FTD (bv-FTD) patients. In particular, PEA-LUT treatment could be able to reduce behavioural disturbances, the more disabling symptoms in bv-FTD, with a related improvement of daily living activities of affected people. Moreover, a multimodal approach (cognitive/neurophysiological) can be used to assess the brain correlates related to the clinical improvement associated with PEA-LUT treatment, thus making remarkable strides in understanding how FTD affects the brain. Potentially the proposed project could provide a valid treatment for cognitive and behavioural dysfunction in FTD patients, with consistent impact for the National Health Systems and minimum cost for the patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
| Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
| Active, not recruiting |
NCT03987295 -
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
|
Phase 2 | |
| Withdrawn |
NCT05497817 -
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
|
N/A | |
| Recruiting |
NCT04918251 -
EEG and TMS-based Biomarkers of ALS, MS and FTD
|
||
| Completed |
NCT01002300 -
Oxytocin and Social Cognition in Frontotemporal Dementia
|
N/A | |
| Completed |
NCT01890343 -
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
|
Phase 2 | |
| Completed |
NCT00376051 -
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
|
Phase 4 | |
| Terminated |
NCT00159198 -
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
Phase 1 | |
| Active, not recruiting |
NCT04516499 -
Neurofilament Surveillance Project (NSP)
|
||
| Recruiting |
NCT04747431 -
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
|
Phase 1/Phase 2 | |
| Completed |
NCT03636204 -
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
|
Phase 1 | |
| Completed |
NCT01937013 -
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
|
Phase 2 | |
| Active, not recruiting |
NCT05075187 -
Epidemiological Study in FRONtoTemporal Dementia
|
||
| Not yet recruiting |
NCT05004558 -
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
|
N/A | |
| Completed |
NCT02999282 -
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects
|
N/A | |
| Completed |
NCT00594737 -
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
|
Phase 3 | |
| Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
| Active, not recruiting |
NCT04993755 -
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
|
Phase 2 | |
| Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|